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Background
Honey bee (HB) venom immunotherapy (HBVIT) reduces
the frequency of immediate generalised reactions (IGR) to
subsequent sting by only ~ 80% and in the process induces
IGR in many subjects. In influenza vaccine studies delta
inulin adjuvant enhanced immunogenicity and provided
antigen-sparing without any adverse reactions. In an
ongoing double-blinded clinical trial we are studying the
benefits of inulin adjuvant for HBVIT.
Methods
Following institutional ethics committee approval, 26 sub-
jects with a history of IGR to HB sting were randomized
2:1 to receive Albey (Stallergenes) HBVIT (100 mcg main-
tenance) by clustered, semi-rush regime with (gp A) or
without (gp B) Advax™ inulin adjuvant (Vaxine Pty Ltd).
Specific IgE (sIgE) was measured by CAP, and specific
IgG1 and IgG4 by ELISA.
Results
Clinicians remain blinded to patient randomization. Two
subjects have withdrawn for personal reasons. One subject
had two anaphylactic reactions at 3 and 100ug of venom,
was withdrawn and on breaking code was in gp B (no
adjuvant). Two other subjects had mild systemic reactions.
A major difference between groups is apparent in sIgG4
responses. Both groups showed a peak sIgG4 response at
14 weeks (early maintenance HBVIT). In gp A however,
the sIgG4 rise started earlier, the peak response was much
higher and after 12 months of maintenance HBVIT, sIgG4
levels were ~3 fold higher by ELISA OD [results mean
(SEM); baseline gp A 0.110 (0.032),gp B 0.076 (0.038),
peak .gp A .0.822 (0.155), gp B 0.326 ((0.106), 52 weeks
gp A 0.453 (0.223) gp B 0.170 (0.059)]. sIgE responses
showed a wide scatter with a rise from baseline of similar
magnitude but occurring earlier in group A, followed by a
progressive fall, [baseline gp A 0.960 ((0.171), gp B 0.624
(0.138), peak gp A. 1.242 (0.154), gp B 0.888 (0.163),
52 weeks gp A 0.862 (0.243), gp B 0.541 (0.117)]. sIgG1
responses showed a similar pattern.
Conclusions
With the caveat that only surrogate markers have yet
been analysed, delta inulin adjuvant appears to enhance
the immunogenicity of HBVIT and to favour sIgG4
responses.
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